Eliem Therapeutics (NASDAQ:ELYM) Stock Price Down 0.3% – Here’s What Happened

Eliem Therapeutics, Inc. (NASDAQ:ELYM) shares dropped 0.3% on Thursday . The company traded as low as $16.58 and last traded at $17.34. 1,286,595 shares changed hands during trading, an increase of 164% from the average daily volume of 486,688 shares. The stock had previously closed at $17.39.

Eliem Therapeutics Stock Performance

The business has a fifty day simple moving average of $13.23 and a 200 day simple moving average of $9.96. The stock has a market cap of $514.11 million, a price-to-earnings ratio of -32.60 and a beta of -0.39.

About Eliem Therapeutics

Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.

The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.